HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

OTC Naloxone Nasal Spray Biocompatibility Study Funded In US From Purdue Pharma Bankruptcy

Executive Summary

Up to $6.5m funding will completely cover Harm Reduction Therapeutics' costs for a Phase 1 study, preparation of an NDA and commercial launch production. The study, a standard Phase 1 biocompatibility trial with around 30 subjects, should be completed in a few months later this summer.

You may also be interested in...



OTC Narcan’s Shelf-Life Extended A Year, RiVive Naloxone Shipments Launched To Nonprofits

Emergent extends shelf-life of newly manufactured Narcan from three years to four years at FDA’s request; nonprofit pharma Harm Reduction Therapeutics ships first order of RiVive to overdose prevention advocacy group Remedy Alliance/For the People.

HRT Prioritizes Access To Affordable Naloxone As US FDA Approves Second OTC Formulation

Co-founder and CEO Michael Hufford says HRT hopes to distribute first commercial supply in early 2024. Firm is engaging additional funding partners to help make its affordable opioid overdose treatment more accessible.

Nasal Naloxone On Brink Of OTC Among Additional Opioid Overdose Options On US FDA's Plate

Upcoming goal dates for Emergent’s Narcan and Harm Reduction Therapeutics’ RiVive will test the US FDA’s efforts to nurture the over-the-counter naloxone switch, followed by decisions on higher strength nasal opioid antagonist products from Opiant and Orexo to address fentanyl and other synthetic opioids. 

Related Content

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

RS150156

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel